About this Research Topic
In this Research Topic we would like to explore novel dosing schedules, combinatorial approaches and modalities for cancer treatment in pre-clinical translational models or clinical research. We welcome Original Research Articles, Reviews and Mini-reviews, including but not limited to the following topics:
1. Mechanism of action and signaling pathways central to the change in conventional dosing paradigms or combinatorial approaches.
2. Identification of gene signature or prognostic markers that predict response to treatment modifications.
3. Identification of new targets based on novel therapeutic approaches.
4. Novel approaches to administering targeted therapies (e.g. tyrosine kinase inhibitors) that synergize well with immunotherapy.
5. Use of pharmacokinetics and pharmacodynamics to inform on modifying dosing schedules of standard of care agents.
Dr. Perera and Dr. Snyder are employees of and own stock in Merck, Inc. All other Topic Editors declare no conflict of interest in relation to the Research Topic theme.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Keywords: combination therapy, chemotherapy, dosing schedules, targeted therapies
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.